: The AMEDEO Literature Guide

Home The Word Brain

My Amedeo

FAQ

Privacy

About

Flying Publisher

OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

Prostate Cancer

Free Subscription

Articles published in Prostate
Retrieve available abstracts of 330 articles:
HTML format
Text format

Single Articles

June 2018

BARATA P, Emamekhoo H, Mendiratta P, Koshkin V, et al
Treatment selection for men with metastatic prostate cancer who progress on upfront chemo-hormonal therapy.
Prostate. 2018 Jun 7. doi: 10.1002/pros.23663.
PubMed Text format Abstract available

CHOUDHURY AD, Gray KP, Supko JG, Harshman LC, et al
A dose finding clinical trial of cabozantinib (XL184) administered in combination with abiraterone acetate in metastatic castration-resistant prostate cancer.
Prostate. 2018 Jun 7. doi: 10.1002/pros.23662.
PubMed Text format Abstract available

CHAKRAVARTHI BVSK, Goswami MT, Pathi SS, Dodson M, et al
Expression and role of PAICS, a de novo purine biosynthetic gene in prostate cancer.
Prostate. 2018;78:693-694.
PubMed Text format

May 2018

MIYAHIRA AK, Soule HR
The 24th Annual Prostate Cancer Foundation scientific retreat report.
Prostate. 2018 May 15. doi: 10.1002/pros.23651.
PubMed Text format Abstract available

AL SALEH HA, Haas-Neill S, Al-Hashimi A, Kapoor A, et al
Thrombotic characteristics of extracellular vesicles derived from prostate cancer cells.
Prostate. 2018 May 15. doi: 10.1002/pros.23653.
PubMed Text format Abstract available

JARVIS C, Nelius T, Martinez-Marin D, Sennoune SR, et al
Cabazitaxel regimens inhibit the growth of prostate cancer cells and enhances the anti-tumor properties of PEDF with various efficacy and toxicity.
Prostate. 2018 May 10. doi: 10.1002/pros.23647.
PubMed Text format Abstract available

MUNOZ-MORENO L, Schally AV, Prieto JC, Carmena MJ, et al
Growth hormone-releasing hormone receptor antagonists modify molecular machinery in the progression of prostate cancer.
Prostate. 2018 May 10. doi: 10.1002/pros.23648.
PubMed Text format Abstract available

TINAY I, Tan M, Gui B, Werner L, et al
Functional roles and potential clinical application of miRNA-345-5p in prostate cancer.
Prostate. 2018 May 10. doi: 10.1002/pros.23650.
PubMed Text format Abstract available

ALLOTT EH, Farnan L, Steck SE, Song L, et al
Statin use, high cholesterol and prostate cancer progression; results from HCaP-NC.
Prostate. 2018 May 1. doi: 10.1002/pros.23644.
PubMed Text format Abstract available

MIYAHIRA AK, Pienta KJ, Morris MJ, Bander NH, et al
Meeting report from the Prostate Cancer Foundation PSMA-directed radionuclide scientific working group.
Prostate. 2018 May 1. doi: 10.1002/pros.23642.
PubMed Text format Abstract available

April 2018

ISHII K, Sasaki T, Iguchi K, Kajiwara S, et al
Interleukin-6 induces VEGF secretion from prostate cancer cells in a manner independent of androgen receptor activation.
Prostate. 2018 Apr 29. doi: 10.1002/pros.23643.
PubMed Text format Abstract available

FRANCINI E, Gray KP, Xie W, Shaw GK, et al
Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC).
Prostate. 2018 Apr 29. doi: 10.1002/pros.23645.
PubMed Text format Abstract available

BEYENE DA, Naab TJ, Kanarek NF, Apprey V, et al
Differential expression of Annexin 2, SPINK1, and Hsp60 predict progression of prostate cancer through bifurcated WHO Gleason score categories in African American men.
Prostate. 2018 Apr 22. doi: 10.1002/pros.23537.
PubMed Text format Abstract available

BAYAT H, Narouie B, Ziaee SM, Mowla SJ, et al
Two long non-coding RNAs, Prcat17.3 and Prcat38, could efficiently discriminate benign prostate hyperplasia from prostate cancer.
Prostate. 2018 Apr 19. doi: 10.1002/pros.23538.
PubMed Text format Abstract available

MILLER EA, Pinsky PF, Black A, Andriole GL, et al
Secondary prostate cancer screening outcomes by race in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Screening Trial.
Prostate. 2018 Apr 17. doi: 10.1002/pros.23540.
PubMed Text format Abstract available

POMPE RS, Tilki D, Preisser F, Leyh-Bannurah SR, et al
Survival benefit of local versus no local treatment for metastatic prostate cancer-Impact of baseline PSA and metastatic substages.
Prostate. 2018 Apr 16. doi: 10.1002/pros.23519.
PubMed Text format Abstract available

KOSTOVA MB, Brennen WN, Lopez D, Anthony L, et al
PSA-alpha-2-macroglobulin complex is enzymatically active in the serum of patients with advanced prostate cancer and can degrade circulating peptide hormones.
Prostate. 2018 Apr 16. doi: 10.1002/pros.23539.
PubMed Text format Abstract available

GIRI VN, Obeid E, Hegarty SE, Gross L, et al
Understanding of multigene test results among males undergoing germline testing for inherited prostate cancer: Implications for genetic counseling.
Prostate. 2018 Apr 14. doi: 10.1002/pros.23535.
PubMed Text format Abstract available

MORI K, Kimura T, Ito K, Onuma H, et al
Earlier use of androgen receptor-axis-targeted drugs may improve overall survival in patients with non-metastatic castration-resistant prostate cancer.
Prostate. 2018 Apr 10. doi: 10.1002/pros.23534.
PubMed Text format Abstract available

BRATT O
RE: Preissner F, et al. extent of lymph node dissection improves survival in prostate cancer patients treated with radical prostatectomy without lymph node invasion. The Prostate. 2018;1-7.
Prostate. 2018 Apr 6. doi: 10.1002/pros.23520.
PubMed Text format

KRANZBUHLER B, Salemi S, Umbricht CA, Muller C, et al
Pharmacological upregulation of prostate-specific membrane antigen (PSMA) expression in prostate cancer cells.
Prostate. 2018 Apr 6. doi: 10.1002/pros.23522.
PubMed Text format Abstract available

PRENCIPE M, Fabre A, Murphy TB, Vargyas E, et al
Role of serum response factor expression in prostate cancer biochemical recurrence.
Prostate. 2018 Apr 2. doi: 10.1002/pros.23516.
PubMed Text format Abstract available

PREISSER F, Bandini M, Graefen M, Tilki D, et al
Reply to the letter to the editor: RE: Preisser F, et al. Extent of lymph node dissection improves survival in prostate cancer patients treated with radical prostatectomy without lymph node invasion. The Prostate. 2018;1-7.
Prostate. 2018 Apr 2. doi: 10.1002/pros.23521.
PubMed Text format

March 2018

GAO X, Mao YH, Xiao C, Li K, et al
Calpain-2 triggers prostate cancer metastasis via enhancing CRMP4 promoter methylation through NF-kappaB/DNMT1 signaling pathway.
Prostate. 2018 Mar 30. doi: 10.1002/pros.23512.
PubMed Text format Abstract available

BABCOOK MA, Akgul M, Margevicius S, MacLennan GT, et al
Ser-486/491 phosphorylation and inhibition of AMPKalpha activity is positively associated with Gleason score, metastasis, and castration-resistance in prostate cancer: A retrospective clinical study.
Prostate. 2018 Mar 26. doi: 10.1002/pros.23515.
PubMed Text format Abstract available

BRENNEN WN, Isaacs JT
The what, when, and why of human prostate cancer xenografts.
Prostate. 2018 Mar 24. doi: 10.1002/pros.23510.
PubMed Text format Abstract available

LINXWEILER J, Korbel C, Muller A, Hammer M, et al
A novel mouse model of human prostate cancer to study intraprostatic tumor growth and the development of lymph node metastases.
Prostate. 2018 Mar 24. doi: 10.1002/pros.23508.
PubMed Text format Abstract available

AKINBOYE ES, Rogers OC, Isaacs JT
2-fluoro-5-maleimidobenzoic acid-linked albumin drug (MAD) delivery for selective systemic targeting of metastatic prostate cancer.
Prostate. 2018 Mar 24. doi: 10.1002/pros.23494.
PubMed Text format Abstract available

CAMPOS C, Sotomayor P, Jerez D, Gonzalez J, et al
Exercise and prostate cancer: From basic science to clinical applications.
Prostate. 2018 Mar 23. doi: 10.1002/pros.23502.
PubMed Text format Abstract available

CHEN J, Oromendia C, Halpern JA, Ballman KV, et al
National trends in management of localized prostate cancer: A population based analysis 2004-2013.
Prostate. 2018 Mar 14. doi: 10.1002/pros.23496.
PubMed Text format Abstract available

WANG Y, Xu H, Si L, Li Q, et al
MiR-206 inhibits proliferation and migration of prostate cancer cells by targeting CXCL11.
Prostate. 2018 Mar 14. doi: 10.1002/pros.23468.
PubMed Text format Abstract available

DAVID SN, Arnold Egloff SA, Goyal R, Clark PE, et al
MAGI2 is an independent predictor of biochemical recurrence in prostate cancer.
Prostate. 2018 Mar 14. doi: 10.1002/pros.23506.
PubMed Text format Abstract available

CARLETON NM, Zhu G, Gorbounov M, Miller MC, et al
PBOV1 as a potential biomarker for more advanced prostate cancer based on protein and digital histomorphometric analysis.
Prostate. 2018 Mar 9. doi: 10.1002/pros.23499.
PubMed Text format Abstract available

KEAM SP, Gulati T, Gamell C, Caramia F, et al
Exploring the oncoproteomic response of human prostate cancer to therapeutic radiation using data-independent acquisition (DIA) mass spectrometry.
Prostate. 2018 Mar 9. doi: 10.1002/pros.23500.
PubMed Text format Abstract available

HAYMAN J, Phillips R, Chen D, Perin J, et al
Detectable end of radiation prostate specific antigen assists in identifying men with unfavorable intermediate-risk prostate cancer at high risk of distant recurrence and cancer-specific mortality.
Prostate. 2018 Mar 9. doi: 10.1002/pros.23507.
PubMed Text format Abstract available

WU Y, Yu H, Zheng SL, Na R, et al
A comprehensive evaluation of CHEK2 germline mutations in men with prostate cancer.
Prostate. 2018 Mar 9. doi: 10.1002/pros.23505.
PubMed Text format Abstract available

OKEGAWA T, Ninomiya N, Masuda K, Nakamura Y, et al
AR-V7 in circulating tumor cells cluster as a predictive biomarker of abiraterone acetate and enzalutamide treatment in castration-resistant prostate cancer patients.
Prostate. 2018 Mar 5. doi: 10.1002/pros.23501.
PubMed Text format Abstract available

February 2018

COPELAND BT, Pal SK, Bolton EC, Jones JO, et al
The androgen receptor malignancy shift in prostate cancer.
Prostate. 2018 Feb 23. doi: 10.1002/pros.23497.
PubMed Text format Abstract available

ITO K, Kimura T, Onuma H, Tabata R, et al
Does docetaxel prolong survival of patients with non-metastatic castration-resistant prostate cancer?
Prostate. 2018 Feb 23. doi: 10.1002/pros.23493.
PubMed Text format Abstract available

MACCINI MA, Westfall NJ, Van Bokhoven A, Lucia MS, et al
The effect of digital rectal exam on the 4Kscore for aggressive prostate cancer.
Prostate. 2018 Feb 19. doi: 10.1002/pros.23495.
PubMed Text format Abstract available

PREISSER F, Bandini M, Marchioni M, Nazzani S, et al
Extent of lymph node dissection improves survival in prostate cancer patients treated with radical prostatectomy without lymph node invasion.
Prostate. 2018 Feb 19. doi: 10.1002/pros.23491.
PubMed Text format Abstract available

SHOU J, Zhang Q, Wang S, Zhang D, et al
The prognosis of different distant metastases pattern in prostate cancer: A population based retrospective study.
Prostate. 2018 Feb 13. doi: 10.1002/pros.23492.
PubMed Text format Abstract available

DE LAERE B, Oeyen S, Van Oyen P, Ghysel C, et al
Circulating tumor cells and survival in abiraterone- and enzalutamide-treated patients with castration-resistant prostate cancer.
Prostate. 2018 Feb 12. doi: 10.1002/pros.23488.
PubMed Text format Abstract available

SILVA JAF, Bruni-Cardoso A, Augusto TM, Damas-Souza DM, et al
Macrophage roles in the clearance of apoptotic cells and control of inflammation in the prostate gland after castration.
Prostate. 2018;78:95-103.
PubMed Text format Abstract available

RODRIGO MAM, Strmiska V, Horackova E, Buchtelova H, et al
Sarcosine influences apoptosis and growth of prostate cells via cell-type specific regulation of distinct sets of genes.
Prostate. 2018;78:104-112.
PubMed Text format Abstract available

January 2018

JIANG X, Huang Y, Liang X, Jiang F, et al
Metastatic prostate cancer-associated P62 inhibits autophagy flux and promotes epithelial to mesenchymal transition by sustaining the level of HDAC6.
Prostate. 2018 Jan 31. doi: 10.1002/pros.23487.
PubMed Text format Abstract available

KARLSSON T, Sundar R, Widmark A, Landstrom M, et al
Osteoblast-derived factors promote metastatic potential in human prostate cancer cells, in part via non-canonical transforming growth factor beta (TGFbeta) signaling.
Prostate. 2018 Jan 31. doi: 10.1002/pros.23489.
PubMed Text format Abstract available

MCDONALD AC, Vira M, Shen J, Sanda M, et al
Circulating microRNAs in plasma as potential biomarkers for the early detection of prostate cancer.
Prostate. 2018 Jan 31. doi: 10.1002/pros.23485.
PubMed Text format Abstract available

WANG L, Kim D, Wise JTF, Shi X, et al
p62 as a therapeutic target for inhibition of autophagy in prostate cancer.
Prostate. 2018 Jan 25. doi: 10.1002/pros.23483.
PubMed Text format Abstract available

WURNSCHIMMEL C, Grande P, Moschini M, Ferrari M, et al
Accuracy of standardized 12-core template biopsies versus non-standardized biopsies for detection of Epstein Grade 5 prostate cancer regarding the histology of the prostatectomy specimen.
Prostate. 2018 Jan 25. doi: 10.1002/pros.23480.
PubMed Text format Abstract available

ISAACSSON VELHO P, Silberstein JL, Markowski MC, Luo J, et al
Intraductal/ductal histology and lymphovascular invasion are associated with germline DNA-repair gene mutations in prostate cancer.
Prostate. 2018 Jan 25. doi: 10.1002/pros.23484.
PubMed Text format Abstract available

MIKI J, Yanagisawa T, Tsuzuki S, Mori K, et al
Anatomical localization and clinical impact of sentinel lymph nodes based on patterns of pelvic lymphatic drainage in clinically localized prostate cancer.
Prostate. 2018 Jan 25. doi: 10.1002/pros.23486.
PubMed Text format Abstract available

DU Z, Lubmawa A, Gundell S, Wan P, et al
Genetic risk of prostate cancer in ugandan men.
Prostate. 2018 Jan 21. doi: 10.1002/pros.23481.
PubMed Text format Abstract available

BEEBE-DIMMER JL, Zuhlke KA, Johnson AM, Liesman D, et al
Rare germline mutations in African American men diagnosed with early-onset prostate cancer.
Prostate. 2018 Jan 21. doi: 10.1002/pros.23464.
PubMed Text format Abstract available

HUANG H, Wang Q, Du T, Lin C, et al
Matrine inhibits the progression of prostate cancer by promoting expression of GADD45B.
Prostate. 2018 Jan 21. doi: 10.1002/pros.23469.
PubMed Text format Abstract available

SU Z, Zhang M, Xu M, Li X, et al
MicroRNA181c inhibits prostate cancer cell growth and invasion by targeting multiple ERK signaling pathway components.
Prostate. 2018 Jan 16. doi: 10.1002/pros.23478.
PubMed Text format Abstract available

KIMBROUGH-ALLAH MN, Millena AC, Khan SA
Differential role of PTEN in transforming growth factor beta (TGF-beta) effects on proliferation and migration in prostate cancer cells.
Prostate. 2018 Jan 16. doi: 10.1002/pros.23482.
PubMed Text format Abstract available

HENDRIKS RJ, Dijkstra S, Smit FP, Vandersmissen J, et al
Epigenetic markers in circulating cell-free DNA as prognostic markers for survival of castration-resistant prostate cancer patients.
Prostate. 2018 Jan 12. doi: 10.1002/pros.23477.
PubMed Text format Abstract available

XU L, Shen M, Chen X, Zhu R, et al
Adipocytes affect castration-resistant prostate cancer cells to develop the resistance to cytotoxic action of NK cells with alterations of PD-L1/NKG2D ligand levels in tumor cells.
Prostate. 2018 Jan 12. doi: 10.1002/pros.23479.
PubMed Text format Abstract available

AZUMA T
Comparing sequencing of abiraterone and enzalutamide in men with metastatic castration-resistant prostate cancer: A retrospective study.
Prostate. 2018 Jan 8. doi: 10.1002/pros.23470.
PubMed Text format

ALBITAR M, Ma W, Lund L, Shahbaba B, et al
Prostatectomy-based validation of combined urine and plasma test for predicting high grade prostate cancer.
Prostate. 2018 Jan 8. doi: 10.1002/pros.23473.
PubMed Text format Abstract available

EKOUE DN, Ansong E, Liu L, Macias V, et al
Correlations of SELENOF and SELENOP genotypes with serum selenium levels and prostate cancer.
Prostate. 2018 Jan 5. doi: 10.1002/pros.23471.
PubMed Text format Abstract available

LIN HM, Lee BY, Castillo L, Spielman C, et al
Effect of FAK inhibitor VS-6063 (defactinib) on docetaxel efficacy in prostate cancer.
Prostate. 2018 Jan 5. doi: 10.1002/pros.23476.
PubMed Text format Abstract available

TYAGI P, Motley SS, Koyama T, Kashyap M, et al
Molecular correlates in urine for the obesity and prostatic inflammation of BPH/LUTS patients.
Prostate. 2018;78:17-24.
PubMed Text format Abstract available

December 2017

VAN DER TOOM EE, Groot VP, Glavaris SA, Gemenetzis G, et al
Analogous detection of circulating tumor cells using the AccuCyte((R)) -CyteFinder((R)) system and ISET system in patients with locally advanced and metastatic prostate cancer.
Prostate. 2017 Dec 29. doi: 10.1002/pros.23474.
PubMed Text format Abstract available

FAN L, Wang R, Chi C, Cai W, et al
Systemic immune-inflammation index predicts the combined clinical outcome after sequential therapy with abiraterone and docetaxel for metastatic castration-resistant prostate cancer patients.
Prostate. 2017 Dec 29. doi: 10.1002/pros.23465.
PubMed Text format Abstract available

MCLEOD AB, Stice JP, Wardell SE, Alley HM, et al
Validation of histone deacetylase 3 as a therapeutic target in castration-resistant prostate cancer.
Prostate. 2017 Dec 15. doi: 10.1002/pros.23467.
PubMed Text format Abstract available

ZUMSTEG ZS, Chen Z, Howard LE, Amling CL, et al
Modified risk stratification grouping using standard clinical and biopsy information for patients undergoing radical prostatectomy: Results from SEARCH.
Prostate. 2017;77:1592-1600.
PubMed Text format Abstract available

ZHOU CK, Stanczyk FZ, Hafi M, Veneroso CC, et al
Circulating and intraprostatic sex steroid hormonal profiles in relation to male pattern baldness and chest hair density among men diagnosed with localized prostate cancers.
Prostate. 2017;77:1573-1582.
PubMed Text format Abstract available

BAUER SR, Van Blarigan EL, Stampfer MJ, Chan JM, et al
Mediterranean diet after prostate cancer diagnosis and urinary and sexual functioning: The health professionals follow-up study.
Prostate. 2017 Dec 1. doi: 10.1002/pros.23457.
PubMed Text format Abstract available

ANDO T, Nishiyama T, Takizawa I, Miyashiro Y, et al
A carbon 21 steroidal metabolite from progestin, 20beta-hydroxy-5alpha-dihydroprogesterone, stimulates the androgen receptor in prostate cancer cells.
Prostate. 2017 Dec 1. doi: 10.1002/pros.23460.
PubMed Text format Abstract available

FIANDALO MV, Wilton JH, Mantione KM, Wrzosek C, et al
Serum-free complete medium, an alternative medium to mimic androgen deprivation in human prostate cancer cell line models.
Prostate. 2017 Dec 1. doi: 10.1002/pros.23459.
PubMed Text format Abstract available

November 2017

YAN G, Ru Y, Wu K, Yan F, et al
GOLM1 promotes prostate cancer progression through activating PI3K-AKT-mTOR signaling.
Prostate. 2017 Nov 27. doi: 10.1002/pros.23461.
PubMed Text format Abstract available

CHEN H, Ewing CM, Zheng S, Grindedaal EM, et al
Genetic factors influencing prostate cancer risk in Norwegian men.
Prostate. 2017 Nov 27. doi: 10.1002/pros.23453.
PubMed Text format Abstract available

JOSHU CE, Peskoe SB, Heaphy CM, Kenfield SA, et al
Current or recent smoking is associated with more variable telomere length in prostate stromal cells and prostate cancer cells.
Prostate. 2017 Nov 22. doi: 10.1002/pros.23462.
PubMed Text format Abstract available

TSUI KH, Chang YL, Feng TH, Hou CP, et al
Capillarisin blocks prostate-specific antigen expression on activation of androgen receptor in prostate carcinoma cells.
Prostate. 2017 Nov 22. doi: 10.1002/pros.23463.
PubMed Text format Abstract available

FACINA CH, Campos SGP, Goncalves BF, Goes RM, et al
Long-term oral exposure to safe dose of bisphenol A in association with high-fat diet stimulate the prostatic lesions in a rodent model for prostate cancer.
Prostate. 2017 Nov 17. doi: 10.1002/pros.23458.
PubMed Text format Abstract available

GHASHGHAEI M, Paliouras M, Heravi M, Bekerat H, et al
Enhanced radiosensitization of enzalutamide via schedule dependent administration to androgen-sensitive prostate cancer cells.
Prostate. 2017 Nov 14. doi: 10.1002/pros.23445.
PubMed Text format Abstract available

KALSBEEK AMF, Chan EKF, Grogan J, Petersen DC, et al
Altered mitochondrial genome content signals worse pathology and prognosis in prostate cancer.
Prostate. 2017 Nov 14. doi: 10.1002/pros.23440.
PubMed Text format Abstract available

COARFA C, Florentin D, Putluri N, Ding Y, et al
Influence of the neural microenvironment on prostate cancer.
Prostate. 2017 Nov 13. doi: 10.1002/pros.23454.
PubMed Text format Abstract available

TAT D, Kenfield SA, Cowan JE, Broering JM, et al
Milk and other dairy foods in relation to prostate cancer recurrence: Data from the cancer of the prostate strategic urologic research endeavor (CaPSURE).
Prostate. 2017 Nov 6. doi: 10.1002/pros.23441.
PubMed Text format Abstract available

MARTINO T, Kudrolli TA, Kumar B, Salviano I, et al
The orally active pterocarpanquinone LQB-118 exhibits cytotoxicity in prostate cancer cell and tumor models through cellular redox stress.
Prostate. 2017 Nov 6. doi: 10.1002/pros.23455.
PubMed Text format Abstract available

CHENG HH, Plets M, Li H, Higano CS, et al
Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer.
Prostate. 2017 Nov 6. doi: 10.1002/pros.23452.
PubMed Text format Abstract available

XIAO H, Wang J, Yan W, Cui Y, et al
GLUT1 regulates cell glycolysis and proliferation in prostate cancer.
Prostate. 2017 Nov 6. doi: 10.1002/pros.23448.
PubMed Text format Abstract available

SCHMIDKONZ C, Hollweg C, Beck M, Reinfelder J, et al
99m Tc-MIP-1404-SPECT/CT for the detection of PSMA-positive lesions in 225 patients with biochemical recurrence of prostate cancer.
Prostate. 2017 Nov 6. doi: 10.1002/pros.23444.
PubMed Text format Abstract available

DAVIDSSON S, Andren O, Ohlson AL, Carlsson J, et al
FOXP3+ regulatory T cells in normal prostate tissue, postatrophic hyperplasia, prostatic intraepithelial neoplasia, and tumor histological lesions in men with and without prostate cancer.
Prostate. 2017 Nov 6. doi: 10.1002/pros.23442.
PubMed Text format Abstract available

BONKHOFF H
Estrogen receptor signaling in prostate cancer: Implications for carcinogenesis and tumor progression.
Prostate. 2017 Nov 2. doi: 10.1002/pros.23446.
PubMed Text format Abstract available

KATO M, Kimura K, Hirakawa A, Kobayashi Y, et al
Prognostic parameter for high risk prostate cancer patients at initial presentation.
Prostate. 2017 Nov 2. doi: 10.1002/pros.23438.
PubMed Text format Abstract available

TJON-KON-FAT LA, Lundholm M, Schroder M, Wurdinger T, et al
Platelets harbor prostate cancer biomarkers and the ability to predict therapeutic response to abiraterone in castration resistant patients.
Prostate. 2017 Nov 2. doi: 10.1002/pros.23443.
PubMed Text format Abstract available

NESBITT H, Worthington J, Errington RJ, Patterson LH, et al
The unidirectional hypoxia-activated prodrug OCT1002 inhibits growth and vascular development in castrate-resistant prostate tumors.
Prostate. 2017;77:1539-1547.
PubMed Text format Abstract available

October 2017

STARK TW, Hensley PJ, Spear A, Pu H, et al
Predictive value of epithelial-mesenchymal-transition (EMT) signature and PARP-1 in prostate cancer radioresistance.
Prostate. 2017 Oct 23. doi: 10.1002/pros.23435.
PubMed Text format Abstract available

WOODS-BURNHAM L, Basu A, Cajigas-Du Ross CK, Love A, et al
The 22Rv1 prostate cancer cell line carries mixed genetic ancestry: Implications for prostate cancer health disparities research using pre-clinical models.
Prostate. 2017 Oct 14. doi: 10.1002/pros.23437.
PubMed Text format Abstract available

LI E, Liu L, Li F, Luo L, et al
PSCA promotes prostate cancer proliferation and cell-cycle progression by up-regulating c-Myc.
Prostate. 2017 Oct 2. doi: 10.1002/pros.23432.
PubMed Text format Abstract available

ABEDINPOUR P, Baron VT, Chrastina A, Rondeau G, et al
Plumbagin improves the efficacy of androgen deprivation therapy in prostate cancer: A pre-clinical study.
Prostate. 2017 Oct 2. doi: 10.1002/pros.23428.
PubMed Text format Abstract available

SHI X, Peng Y, Du X, Liu H, et al
Estradiol promotes epithelial-to-mesenchymal transition in human benign prostatic epithelial cells.
Prostate. 2017;77:1424-1437.
PubMed Text format Abstract available

HAYASHI T, Fujita K, Nojima S, Hayashi Y, et al
Peripheral blood monocyte count reflecting tumor-infiltrating macrophages is a predictive factor of adverse pathology in radical prostatectomy specimens.
Prostate. 2017;77:1383-1388.
PubMed Text format Abstract available

September 2017

BURDELSKI C, Shihada R, Hinsch A, Angerer A, et al
High-Level Glyoxalase 1 (GLO1) expression is linked to poor prognosis in prostate cancer.
Prostate. 2017 Sep 19. doi: 10.1002/pros.23431.
PubMed Text format Abstract available

MIYAHIRA AK, Cheng HH, Abida W, Ellis L, et al
Beyond the androgen receptor II: New approaches to understanding and treating metastatic prostate cancer; Report from the 2017 Coffey-Holden Prostate Cancer Academy Meeting.
Prostate. 2017 Sep 18. doi: 10.1002/pros.23424.
PubMed Text format Abstract available

TSUMURA H, Ishiyama H, Tabata KI, Katsumata H, et al
Impact of five-tiered Gleason grade groups on prognostic prediction in clinical stage T3 prostate cancer undergoing high-dose-rate brachytherapy.
Prostate. 2017 Sep 14. doi: 10.1002/pros.23430.
PubMed Text format Abstract available

KANAYAMA M, Hayano T, Koebis M, Maeda T, et al
Hyperactive mTOR induces neuroendocrine differentiation in prostate cancer cell with concurrent up-regulation of IRF1.
Prostate. 2017 Sep 14. doi: 10.1002/pros.23425.
PubMed Text format Abstract available

PEDRAZA-AREVALO S, Hormaechea-Agulla D, Gomez-Gomez E, Requena MJ, et al
Somatostatin receptor subtype 1 as a potential diagnostic marker and therapeutic target in prostate cancer.
Prostate. 2017 Sep 14. doi: 10.1002/pros.23426.
PubMed Text format Abstract available

STROMVALL K, Sundkvist K, Ljungberg B, Halin Bergstrom S, et al
Reduced number of CD169+ macrophages in pre-metastatic regional lymph nodes is associated with subsequent metastatic disease in an animal model and with poor outcome in prostate cancer patients.
Prostate. 2017 Sep 7. doi: 10.1002/pros.23407.
PubMed Text format Abstract available

YANG CS, Melhuish TA, Spencer A, Ni L, et al
The protein kinase C super-family member PKN is regulated by mTOR and influences differentiation during prostate cancer progression.
Prostate. 2017 Sep 6. doi: 10.1002/pros.23400.
PubMed Text format Abstract available

VINCENEUX A, Bruyere F, Haillot O, Charles T, et al
Ductal adenocarcinoma of the prostate: Clinical and biological profiles.
Prostate. 2017;77:1242-1250.
PubMed Text format Abstract available

August 2017

GINSBURG KB, Elshafei A, Yu C, Jones JS, et al
Avoidance of androgen deprivation therapy in radiorecurrent prostate cancer as a clinically meaningful endpoint for salvage cryoablation.
Prostate. 2017 Aug 29. doi: 10.1002/pros.23406.
PubMed Text format Abstract available

SOEKMADJI C, Corcoran NM, Oleinikova I, Jovanovic L, et al
Extracellular vesicles for personalized therapy decision support in advanced metastatic cancers and its potential impact for prostate cancer.
Prostate. 2017 Aug 29. doi: 10.1002/pros.23403.
PubMed Text format Abstract available

HENDRIKS RJ, van der Leest MMG, Dijkstra S, Barentsz JO, et al
A urinary biomarker-based risk score correlates with multiparametric MRI for prostate cancer detection.
Prostate. 2017 Aug 29. doi: 10.1002/pros.23401.
PubMed Text format Abstract available

SUH JH, Park JH, Lee C, Moon KC, et al
Intrafocal heterogeneity of ERG protein expression and gene fusion pattern in prostate cancer.
Prostate. 2017 Aug 28. doi: 10.1002/pros.23405.
PubMed Text format Abstract available

LIU L, Li E, Luo L, Zhao S, et al
PSCA regulates IL-6 expression through p38/NF-kappaB signaling in prostate cancer.
Prostate. 2017 Aug 28. doi: 10.1002/pros.23399.
PubMed Text format Abstract available

MIYATA Y, Nakamura Y, Yasuda T, Matsuo T, et al
Neoadjuvant hormonal therapy for low-risk prostate cancer induces biochemical recurrence after radical prostatectomy via increased lymphangiogenesis-related parameters.
Prostate. 2017 Aug 28. doi: 10.1002/pros.23402.
PubMed Text format Abstract available

DONG B, Fan L, Wang Y, Chi C, et al
Influence of abiraterone acetate on neuroendocrine differentiation in chemotherapy-naive metastatic castration-resistant prostate cancer.
Prostate. 2017 Aug 14. doi: 10.1002/pros.23397.
PubMed Text format Abstract available

STRUSS WJ, Tan Z, Zachkani P, Moskalev I, et al
Magnetically-actuated drug delivery device (MADDD) for minimally invasive treatment of prostate cancer: An in vivo animal pilot study.
Prostate. 2017 Aug 8. doi: 10.1002/pros.23395.
PubMed Text format Abstract available

PALLER CJ, Cole AP, Partin AW, Carducci MA, et al
Risk factors for metastatic prostate cancer: A sentinel event case series.
Prostate. 2017 Aug 8. doi: 10.1002/pros.23396.
PubMed Text format Abstract available

VAN NESTE L, Groskopf J, Grizzle WE, Adams GW, et al
Epigenetic risk score improves prostate cancer risk assessment.
Prostate. 2017 Aug 1. doi: 10.1002/pros.23385.
PubMed Text format Abstract available

HARSHMAN LC, Werner L, Tripathi A, Wang X, et al
The impact of statin use on the efficacy of abiraterone acetate in patients with castration-resistant prostate cancer.
Prostate. 2017 Aug 1. doi: 10.1002/pros.23390.
PubMed Text format Abstract available

July 2017

FAN L, Wang X, Chi C, Wang Y, et al
Prognostic nutritional index predicts initial response to treatment and prognosis in metastatic castration-resistant prostate cancer patients treated with abiraterone.
Prostate. 2017 Jul 28. doi: 10.1002/pros.23381.
PubMed Text format Abstract available

SUN G, Huang R, Zhang X, Shen P, et al
The impact of multifocal perineural invasion on biochemical recurrence and timing of adjuvant androgen-deprivation therapy in high-risk prostate cancer following radical prostatectomy.
Prostate. 2017 Jul 27. doi: 10.1002/pros.23388.
PubMed Text format Abstract available

SHARPE B, Alghezi DA, Cattermole C, Beresford M, et al
A subset of high Gleason grade prostate carcinomas contain a large burden of prostate cancer syndecan-1 positive stromal cells.
Prostate. 2017 Jul 26. doi: 10.1002/pros.23391.
PubMed Text format Abstract available

LIN X, Chen Z, Gao P, Gao Z, et al
TEX15: A DNA repair gene associated with prostate cancer risk in Han Chinese.
Prostate. 2017 Jul 21. doi: 10.1002/pros.23387.
PubMed Text format Abstract available

AI J, Tai PWL, Lu Y, Li J, et al
Characterization of adenoviral transduction profile in prostate cancer cells and normal prostate tissue.
Prostate. 2017 Jul 20. doi: 10.1002/pros.23386.
PubMed Text format Abstract available

TODENHOFER T, Hennenlotter J, Keller G, Neumann T, et al
Effect of radical prostatectomy on levels of cancer related epitopes in circulating macrophages of patients with clinically localized prostate cancer.
Prostate. 2017 Jul 20. doi: 10.1002/pros.23384.
PubMed Text format Abstract available

BREEN KJ, O'Neill A, Murphy L, Fan Y, et al
Investigating the role of the IGF axis as a predictor of biochemical recurrence in prostate cancer patients post-surgery.
Prostate. 2017 Jul 20. doi: 10.1002/pros.23389.
PubMed Text format Abstract available

CHEN H, Na R, Packiam VT, Conran CA, et al
Reclassification of prostate cancer risk using sequentially identified SNPs: Results from the REDUCE trial.
Prostate. 2017 Jul 2. doi: 10.1002/pros.23369.
PubMed Text format Abstract available

DE BARI B, Stish B, Ball MW, Habboush Y, et al
Adult prostatic sarcoma: A contemporary multicenter Rare Cancer Network study.
Prostate. 2017;77:1160-1166.
PubMed Text format Abstract available

RODRIGUES TM, Mitre AI, da Silva LFF, Castilho LN, et al
Periprostatic innervation: New issues based on segmental analysis of 10 human cadaver pelvic blocs.
Prostate. 2017;77:1151-1159.
PubMed Text format Abstract available

BOKHORST LP, Roobol MJ, Bangma CH, van Leenders GJ, et al
Effect of pathologic revision and Ki67 and ERG immunohistochemistry on predicting radical prostatectomy outcome in men initially on active surveillance.
Prostate. 2017;77:1137-1143.
PubMed Text format Abstract available

June 2017

LAWAL IO, Ankrah AO, Mokgoro NP, Vorster M, et al
Diagnostic sensitivity of Tc-99m HYNIC PSMA SPECT/CT in prostate carcinoma: A comparative analysis with Ga-68 PSMA PET/CT.
Prostate. 2017 Jun 26. doi: 10.1002/pros.23379.
PubMed Text format Abstract available

CRUMBAKER M, Gurney H
Dose considerations for anti-cancer drugs in metastatic prostate cancer.
Prostate. 2017 Jun 26. doi: 10.1002/pros.23378.
PubMed Text format Abstract available

HE C, Duan S, Dong L, Wang Y, et al
Characterization of a novel p110beta-specific inhibitor BL140 that overcomes MDV3100-resistance in castration-resistant prostate cancer cells.
Prostate. 2017 Jun 20. doi: 10.1002/pros.23377.
PubMed Text format Abstract available

CAI B, Chen W, Pan Y, Chen H, et al
Inhibition of microRNA-500 has anti-cancer effect through its conditional downstream target of TFPI in human prostate cancer.
Prostate. 2017 Jun 20. doi: 10.1002/pros.23361.
PubMed Text format Abstract available

XU Y, Qin S, An T, Tang Y, et al
MiR-145 detection in urinary extracellular vesicles increase diagnostic efficiency of prostate cancer based on hydrostatic filtration dialysis method.
Prostate. 2017 Jun 15. doi: 10.1002/pros.23376.
PubMed Text format Abstract available

ZHAO R, Sun F, Bei X, Wang X, et al
Upregulation of the long non-coding RNA FALEC promotes proliferation and migration of prostate cancer cell lines and predicts prognosis of PCa patients.
Prostate. 2017 Jun 6. doi: 10.1002/pros.23367.
PubMed Text format Abstract available

ARMSTRONG CM, Liu C, Lou W, Lombard AP, et al
MicroRNA-181a promotes docetaxel resistance in prostate cancer cells.
Prostate. 2017;77:1020-1028.
PubMed Text format Abstract available

GONZAGA ACR, Campolina-Silva GH, Werneck-Gomes H, Moura-Cordeiro JD, et al
Profile of cell proliferation and apoptosis activated by the intrinsic and extrinsic pathways in the prostate of aging rats.
Prostate. 2017;77:937-948.
PubMed Text format Abstract available

AJIBOYE AS, Esopi D, Yegnasubramanian S, Denmeade SR, et al
Androgen Receptor Splice Variants Are Not Substrates of Nonsense-Mediated Decay.
Prostate. 2017;77:829-837.
PubMed Text format Abstract available

KIDO LA, Montico F, Vendramini-Costa DB, Pilli RA, et al
Goniothalamin and Celecoxib Effects During Aging: Targeting Pro-Inflammatory Mediators in Chemoprevention of Prostatic Disorders.
Prostate. 2017;77:838-848.
PubMed Text format Abstract available

SHARIF A, Malhotra NR, Acosta AM, Kajdacsy-Balla AA, et al
The Development of Prostate Adenocarcinoma in a Transgender Male to Female Patient: Could Estrogen Therapy Have Played a Role?
Prostate. 2017;77:824-828.
PubMed Text format Abstract available

May 2017

MORI K, Kimura T, Onuma H, Kimura S, et al
Lactate dehydrogenase predicts combined progression-free survival after sequential therapy with abiraterone and enzalutamide for patients with castration-resistant prostate cancer.
Prostate. 2017 May 30. doi: 10.1002/pros.23373.
PubMed Text format Abstract available

KIM Y, Park SE, Moon JW, Kim BM, et al
Downregulation of androgen receptors by NaAsO2 via inhibition of AKT-NF-kappaB and HSP90 in castration resistant prostate cancer.
Prostate. 2017 May 30. doi: 10.1002/pros.23370.
PubMed Text format Abstract available

NUNEZ BRAGAYRAC LA, Murekeyisoni C, Vacchio MJ, Attwood K, et al
Blinded review of archival radical prostatectomy specimens supports that contemporary Gleason score 6 prostate cancer lacks metastatic potential.
Prostate. 2017 May 26. doi: 10.1002/pros.23364.
PubMed Text format Abstract available

IRIZARRY-RAMIREZ M, Kittles RA, Wang X, Salgado-Montilla J, et al
Genetic ancestry and prostate cancer susceptibility SNPs in Puerto Rican and African American men.
Prostate. 2017 May 24. doi: 10.1002/pros.23368.
PubMed Text format Abstract available

MIYAHIRA AK, Soule HR
The 23rd Annual Prostate Cancer Foundation Scientific Retreat report.
Prostate. 2017 May 14. doi: 10.1002/pros.23366.
PubMed Text format Abstract available

NOVAKOVA Z, Foss CA, Copeland BT, Morath V, et al
Novel Monoclonal Antibodies Recognizing Human Prostate-Specific Membrane Antigen (PSMA) as Research and Theranostic Tools.
Prostate. 2017;77:749-764.
PubMed Text format Abstract available

HUANG H, Du T, Zhang Y, Lai Y, et al
Elevation of SHARPIN Protein Levels in Prostate Adenocarcinomas Promotes Metastasis and Impairs Patient Survivals.
Prostate. 2017;77:718-728.
PubMed Text format Abstract available

OLSON BM, Bradley ES, Sawicki T, Zhong W, et al
Safety and Immunological Efficacy of a DNA Vaccine Encoding the Androgen Receptor Ligand-Binding Domain (AR-LBD).
Prostate. 2017;77:812-821.
PubMed Text format Abstract available

POMPE RS, Davis-Bondarenko H, Zaffuto E, Tian Z, et al
Population-Based Validation of the 2014 ISUP Gleason Grade Groups in Patients Treated With Radical Prostatectomy, Brachytherapy, External Beam Radiation, or no Local Treatment.
Prostate. 2017;77:686-693.
PubMed Text format Abstract available

MELITI A, Sadimin E, Diolombi M, Khani F, et al
Accuracy of Grading Gleason Score 7 Prostatic Adenocarcinoma on Needle Biopsy: Influence of Percent Pattern 4 and Other Histological Factors.
Prostate. 2017;77:681-685.
PubMed Text format Abstract available

PIERCONTI F, Martini M, Cenci T, Petrone GL, et al
SOCS3 Immunohistochemical Expression Seems to Support the 2005 and 2014 International Society of Urological Pathology (ISUP) Modified Gleason Grading System.
Prostate. 2017;77:597-603.
PubMed Text format Abstract available

HENNING JD, Karamchandani JM, Bonachea LA, Bunker CH, et al
Elevated Serum PSA is Associated With Human Herpesvirus 8 Infection and Increased Circulating Cytokine Levels in Men From Tobago.
Prostate. 2017;77:617-624.
PubMed Text format Abstract available

BRETT SI, Lucien F, Guo C, Williams KC, et al
Immunoaffinity based methods are superior to kits for purification of prostate derived extracellular vesicles from plasma samples.
Prostate. 2017;77:1335-1343.
PubMed Text format Abstract available

April 2017

SCHALLY AV, Block NL, Rick FG
Discovery of LHRH and development of LHRH analogs for prostate cancer treatment.
Prostate. 2017 Apr 27. doi: 10.1002/pros.23360.
PubMed Text format Abstract available

CONTEDUCA V, Caffo O, Lolli C, Aieta M, et al
Long-term clinical impact of PSA surge in castration-resistant prostate cancer patients treated with abiraterone.
Prostate. 2017 Apr 20. doi: 10.1002/pros.23357.
PubMed Text format Abstract available

JIA L, Gui B, Zheng D, Decker KF, et al
Androgen receptor-regulated miRNA-193a-3p targets AJUBA to promote prostate cancer cell migration.
Prostate. 2017 Apr 19. doi: 10.1002/pros.23356.
PubMed Text format Abstract available

TANG B, Han CT, Gan HL, Zhang GM, et al
Smoking increased the risk of prostate cancer with grade group >/= 4 and intraductal carcinoma in a prospective biopsy cohort.
Prostate. 2017 Apr 19. doi: 10.1002/pros.23354.
PubMed Text format Abstract available

PELLEGRINI KL, Patil D, Douglas KJS, Lee G, et al
Detection of prostate cancer-specific transcripts in extracellular vesicles isolated from post-DRE urine.
Prostate. 2017 Apr 17. doi: 10.1002/pros.23355.
PubMed Text format Abstract available

DE CARVALHO TM, Heijnsdijk EAM, de Koning HJ
When should active surveillance for prostate cancer stop if no progression is detected?
Prostate. 2017 Apr 17. doi: 10.1002/pros.23352.
PubMed Text format Abstract available

GONCALVES BF, de Campos SG, Goes RM, Scarano WR, et al
Dual action of high estradiol doses on MNU-induced prostate neoplasms in a rodent model with high serum testosterone: Protective effect and emergence of unstable epithelial microenvironment.
Prostate. 2017 Apr 12. doi: 10.1002/pros.23353.
PubMed Text format Abstract available

NAKATA D, Koyama R, Nakayama K, Kitazawa S, et al
Glycogen synthase kinase-3 inhibitors suppress the AR-V7-mediated transcription and selectively inhibit cell growth in AR-V7-positive prostate cancer cells.
Prostate. 2017 Apr 10. doi: 10.1002/pros.23351.
PubMed Text format Abstract available

BEAUVAL JB, Cabarrou B, Gandaglia G, Patard PM, et al
External validation of a nomogram for identification of pathologically favorable disease in intermediate risk prostate cancer patients.
Prostate. 2017 Apr 2. doi: 10.1002/pros.23348.
PubMed Text format Abstract available

March 2017

RUNDLE A, Wang Y, Sadasivan S, Chitale DA, et al
Larger men have larger prostates: Detection bias in epidemiologic studies of obesity and prostate cancer risk.
Prostate. 2017 Mar 27. doi: 10.1002/pros.23350.
PubMed Text format Abstract available

HABL G, Sauter K, Schiller K, Dewes S, et al
68 Ga-PSMA-PET for radiation treatment planning in prostate cancer recurrences after surgery: Individualized medicine or new standard in salvage treatment.
Prostate. 2017 Mar 20. doi: 10.1002/pros.23347.
PubMed Text format Abstract available

WINCHESTER DA, Till C, Goodman PJ, Tangen CM, et al
Association between variants in genes involved in the immune response and prostate cancer risk in men randomized to the finasteride arm in the Prostate Cancer Prevention Trial.
Prostate. 2017 Mar 20. doi: 10.1002/pros.23346.
PubMed Text format Abstract available

JOSEFSSON A, Linder A, Flondell Site D, Canesin G, et al
Circulating Tumor Cells as a Marker for Progression-free Survival in Metastatic Castration-naive Prostate Cancer.
Prostate. 2017 Mar 10. doi: 10.1002/pros.23325.
PubMed Text format Abstract available

KHAN S, Cai J, Nielsen ME, Troester MA, et al
The Association of Diabetes and Obesity With Prostate Cancer Progression: HCaP-NC.
Prostate. 2017 Mar 6. doi: 10.1002/pros.23342.
PubMed Text format Abstract available

SZULKIN R, Clements MS, Magnusson PK, Wiklund FE, et al
Estimating Heritability of Prostate Cancer-Specific Survival Using Population-Based Registers.
Prostate. 2017 Mar 1. doi: 10.1002/pros.23344.
PubMed Text format Abstract available

TOLKACH Y, Eminaga O, Wotzel F, Huss S, et al
Blind Biobanking of the Prostatectomy Specimen: Critical Evaluation of the Existing Techniques and Development of the New 4-Level Tissue Extraction Model With High Sampling Efficacy.
Prostate. 2017;77:396-405.
PubMed Text format Abstract available

February 2017

SAETER T, Vlatkovic L, Waaler G, Servoll E, et al
Intraductal Carcinoma of the Prostate on Diagnostic Needle Biopsy Predicts Prostate Cancer Mortality: A Population-Based Study.
Prostate. 2017 Feb 27. doi: 10.1002/pros.23326.
PubMed Text format Abstract available

ZHANG Q, Liu S, Ge D, Cunningham DM, et al
Targeting Th17-IL-17 pathway in prevention of micro-invasive prostate cancer in a mouse model.
Prostate. 2017 Feb 27. doi: 10.1002/pros.23343.
PubMed Text format Abstract available

PILLING AB, Hwang O, Boudreault A, Laurent A, et al
IAP Antagonists Enhance Apoptotic Response to Enzalutamide in Castration-Resistant Prostate Cancer Cells via Autocrine TNF-alpha Signaling.
Prostate. 2017 Feb 27. doi: 10.1002/pros.23327.
PubMed Text format Abstract available

ELSHAFAE SM, Kohart NA, Altstadt LA, Dirksen WP, et al
The Effect of a Histone Deacetylase Inhibitor (AR-42) on Canine Prostate Cancer Growth and Metastasis.
Prostate. 2017 Feb 9. doi: 10.1002/pros.23318.
PubMed Text format Abstract available

VAN DIE MD, Williams SG, Emery J, Bone KM, et al
A Placebo-Controlled Double-Blinded Randomized Pilot Study of Combination Phytotherapy in Biochemically Recurrent Prostate Cancer.
Prostate. 2017 Feb 9. doi: 10.1002/pros.23317.
PubMed Text format Abstract available

LERTSUWAN K, Choe LH, Marwa IR, Lee K, et al
Identification of Fibulin-1 as a Human Bone Marrow Stromal (HS-5) Sell-Derived Factor That Induces Human Prostate Cancer Cell Death.
Prostate. 2017 Feb 7. doi: 10.1002/pros.23303.
PubMed Text format Abstract available

NGUYEN HM, Vessella RL, Morrissey C, Brown LG, et al
LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease an--d Serve as Models for Evaluating Cancer Therapeutics.
Prostate. 2017 Feb 3. doi: 10.1002/pros.23313.
PubMed Text format Abstract available

ISHARWAL S, Modi S, Arora N, Uhlrich C 3rd, et al
Minnelide Inhibits Androgen Dependent, Castration Resistant Prostate Cancer Growth by Decreasing Expression of Androgen Receptor Full Length and Splice Variants.
Prostate. 2017 Feb 1. doi: 10.1002/pros.23298.
PubMed Text format Abstract available

DJUSBERG E, Jernberg E, Thysell E, Golovleva I, et al
High levels of the AR-V7 Splice Variant and Co-Amplification of the Golgi Protein Coding YIPF6 in AR Amplified Prostate Cancer Bone Metastases.
Prostate. 2017 Feb 1. doi: 10.1002/pros.23307.
PubMed Text format Abstract available

DJALADAT H, Amini E, Xu W, Cai J, et al
Oncological Outcomes After Radical Prostatectomy for High-Risk Prostate Cancer Based on New Gleason Grouping System: A Validation Study From University of Southern California With 3,755 Cases.
Prostate. 2017 Feb 1. doi: 10.1002/pros.23306.
PubMed Text format Abstract available

January 2017

FITZGERALD LM, Naeem H, Makalic E, Schmidt DF, et al
Genome-Wide Measures of Peripheral Blood Dna Methylation and Prostate Cancer Risk in a Prospective Nested Case-Control Study.
Prostate. 2017 Jan 24. doi: 10.1002/pros.23289.
PubMed Text format Abstract available

GRAFF RE, Judson G, Ahearn TU, Fiorentino M, et al
Circulating antioxidant levels and risk of prostate cancer by TMPRSS2:ERG.
Prostate. 2017 Jan 19. doi: 10.1002/pros.23312.
PubMed Text format Abstract available

KRATOCHVILOVA M, Raudenska M, Heger Z, Richtera L, et al
Amino Acid Profiling of Zinc Resistant Prostate Cancer Cell Lines: Associations With Cancer Progression.
Prostate. 2017 Jan 19. doi: 10.1002/pros.23304.
PubMed Text format Abstract available

CHOPRA A, Georgieva M, Lopes G, Yeo CM, et al
Abiraterone or Enzalutamide in Advanced Castration-Resistant Prostate Cancer: An Indirect Comparison.
Prostate. 2017 Jan 19. doi: 10.1002/pros.23309.
PubMed Text format Abstract available

WETTSTEIN MS, Saba K, Umbehr MH, Murtola TJ, et al
Prognostic Role of Preoperative Serum Lipid Levels in Patients Undergoing Radical Prostatectomy for Clinically Localized Prostate Cancer.
Prostate. 2017 Jan 17. doi: 10.1002/pros.23296.
PubMed Text format Abstract available

PARIKH RR, Byun J, Goyal S, Kim IY, et al
Local Therapy Improves Overall Survival in Patients With Newly Diagnosed Metastatic Prostate Cancer.
Prostate. 2017 Jan 17. doi: 10.1002/pros.23294.
PubMed Text format Abstract available

LEYH-BANNURAH SR, Budaus L, Pompe R, Zaffuto E, et al
North American Population-Based Validation of the National Comprehensive Cancer Network Practice Guideline Recommendation of Pelvic Lymphadenectomy in Contemporary Prostate Cancer.
Prostate. 2017 Jan 17. doi: 10.1002/pros.23292.
PubMed Text format Abstract available

December 2016

ALVA A, Nordquist L, Daignault S, George S, et al
Clinical Correlates of Benefit From Radium-223 Therapy in Metastatic Castration Resistant Prostate Cancer.
Prostate. 2016 Dec 19. doi: 10.1002/pros.23286.
PubMed Text format Abstract available

CHEN M, Zhou B, Zhong P, Rajamanickam V, et al
Increased Intracellular Reactive Oxygen Species Mediates the Anti-Cancer Effects of WZ35 via Activating Mitochondrial Apoptosis Pathway in Prostate Cancer Cells.
Prostate. 2016 Dec 19. doi: 10.1002/pros.23287.
PubMed Text format Abstract available

FOJ L, Ferrer F, Serra M, Arevalo A, et al
Exosomal and Non-Exosomal Urinary miRNAs in Prostate Cancer Detection and Prognosis.
Prostate. 2016 Dec 19. doi: 10.1002/pros.23295.
PubMed Text format Abstract available

SU S, Parris AB, Grossman G, Mohler JL, et al
Up-Regulation of Follistatin-Like 1 By the Androgen Receptor and Melanoma Antigen-A11 in Prostate Cancer.
Prostate. 2016 Dec 14. doi: 10.1002/pros.23288.
PubMed Text format Abstract available

November 2016

EMAMI NC, Leong L, Wan E, Van Blarigan EL, et al
Tissue Sources for Accurate Measurement of Germline DNA Genotypes in Prostate Cancer Patients Treated With Radical Prostatectomy.
Prostate. 2016 Nov 30. doi: 10.1002/pros.23283.
PubMed Text format Abstract available

MASKO EM, Alfaqih MA, Solomon KR, Barry WT, et al
Evidence for Feedback Regulation Following Cholesterol Lowering Therapy in a Prostate Cancer Xenograft Model.
Prostate. 2016 Nov 30. doi: 10.1002/pros.23282.
PubMed Text format Abstract available

HEMPEL HA, Cuka NS, Kulac I, Barber JR, et al
Low Intratumoral Mast Cells Are Associated With a Higher Risk of Prostate Cancer Recurrence.
Prostate. 2016 Nov 21. doi: 10.1002/pros.23280.
PubMed Text format Abstract available

WANG R, Zeidan AM, Yu JB, Soulos PR, et al
Myelodysplastic Syndromes and Acute Myeloid Leukemia After Radiotherapy for Prostate Cancer: A Population-Based Study.
Prostate. 2016 Nov 21. doi: 10.1002/pros.23281.
PubMed Text format Abstract available

MALDONADO-CARCELES AB, Sanchez-Rodriguez C, Vera-Porras EM, Arense-Gonzalo JJ, et al
Anogenital Distance, a Biomarker of Prenatal Androgen Exposure Is Associated With Prostate Cancer Severity.
Prostate. 2016 Nov 16. doi: 10.1002/pros.23279.
PubMed Text format Abstract available

ARMSTRONG AJ, Humeniuk MS, Healy P, Szmulewitz R, et al
Phase Ib Trial of Cabazitaxel and Tasquinimod in Men With Heavily Pretreated Metastatic Castration Resistant Prostate Cancer (mCRPC): The CATCH Trial.
Prostate. 2016 Nov 16. doi: 10.1002/pros.23277.
PubMed Text format Abstract available

SULEK JE, Robinson SP, Petrossian AA, Zhou S, et al
Role of Epigenetic Modification and Immunomodulation in a Murine Prostate Cancer Model.
Prostate. 2016 Nov 8. doi: 10.1002/pros.23275.
PubMed Text format Abstract available

MIYAZAWA Y, Sekine Y, Kato H, Furuya Y, et al
Simvastatin Up-Regulates Annexin A10 That Can Inhibit the Proliferation, Migration, and Invasion in Androgen-Independent Human Prostate Cancer Cells.
Prostate. 2016 Nov 8. doi: 10.1002/pros.23273.
PubMed Text format Abstract available

GONZALEZ A, Garcia de Durango C, Alonso V, Bravo B, et al
Distinct Osteomimetic Response of Androgen-Dependent and Independent Human Prostate Cancer Cells to Mechanical Action of Fluid Flow: Prometastatic Implications.
Prostate. 2016 Nov 3. doi: 10.1002/pros.23270.
PubMed Text format Abstract available

LEE J, Lee MS, Jeoung DI, Kim YM, et al
Promoter CpG-Site Methylation of the KAI1 Metastasis Suppressor Gene Contributes to Its Epigenetic Repression in Prostate Cancer.
Prostate. 2016 Nov 3. doi: 10.1002/pros.23274.
PubMed Text format Abstract available

PANG J, Yang YW, Huang Y, Yang J, et al
P110beta Inhibition Reduces Histone H3K4 Di-Methylation in Prostate Cancer.
Prostate. 2016 Nov 1. doi: 10.1002/pros.23271.
PubMed Text format Abstract available

MIYAHIRA AK, Morris M, Soule HR
Meeting Report From the Prostate Cancer Foundation Scientific Working Group on Radium-223.
Prostate. 2016 Nov 1. doi: 10.1002/pros.23272.
PubMed Text format Abstract available

REGIS L, Planas J, Carles J, Maldonado X, et al
Free Testosterone During Androgen Deprivation Therapy Predicts Castration-Resistant Progression Better Than Total Testosterone.
Prostate. 2016 Nov 1. doi: 10.1002/pros.23256.
PubMed Text format Abstract available

October 2016

CAPOGROSSO P, Ventimiglia E, Moschini M, Boeri L, et al
Testosterone Levels Correlate With Grade Group 5 Prostate Cancer: Another Step Toward Personalized Medicine.
Prostate. 2016 Oct 24. doi: 10.1002/pros.23266.
PubMed Text format Abstract available

JEFFERS A, Sochat V, Kattan MW, Yu C, et al
Predicting Prostate Cancer Recurrence After Radical Prostatectomy.
Prostate. 2016 Oct 24. doi: 10.1002/pros.23268.
PubMed Text format Abstract available

DEJIMA T, Imada K, Takeuchi A, Shiota M, et al
Suppression of LIM and SH3 Domain Protein 1 (LASP1) Negatively Regulated by Androgen Receptor Delays Castration Resistant Prostate Cancer Progression.
Prostate. 2016 Oct 24. doi: 10.1002/pros.23269.
PubMed Text format Abstract available

GEYBELS MS, McCloskey KD, Mills IG, Stanford JL, et al
Calcium Channel Blocker Use and Risk of Prostate Cancer by TMPRSS2:ERG Gene Fusion Status.
Prostate. 2016 Oct 18. doi: 10.1002/pros.23267.
PubMed Text format Abstract available

DELL'OGLIO P, Karnes RJ, Gandaglia G, Fossati N, et al
The New Prostate Cancer Grading System Does Not Improve Prediction of Clinical Recurrence After Radical Prostatectomy: Results of a Large, Two-Center Validation Study.
Prostate. 2016 Oct 18. doi: 10.1002/pros.23265.
PubMed Text format Abstract available

LEACH DA, Trotta AP, Need EF, Risbridger GP, et al
The prognostic value of stromal FK506-binding protein 1 and androgen receptor in prostate cancer outcome.
Prostate. 2016 Oct 8. doi: 10.1002/pros.23259.
PubMed Text format Abstract available

LIU J, Xiao M, Li J, Wang D, et al
Activation of UPR Signaling Pathway is Associated With the Malignant Progression and Poor Prognosis in Prostate Cancer.
Prostate. 2016 Oct 8. doi: 10.1002/pros.23264.
PubMed Text format Abstract available

DI SEBASTIANO KM, Pinthus JH, Duivenvoorden WC, Patterson L, et al
Elevated C-Peptides, Abdominal Obesity, and Abnormal Adipokine Profile are Associated With Higher Gleason Scores in Prostate Cancer.
Prostate. 2016 Oct 4. doi: 10.1002/pros.23262.
PubMed Text format Abstract available

SHOAIBI A, Rao GA, Cai B, Rawl J, et al
Prostate Specific Antigen-Growth Curve Model to Predict High-Risk Prostate Cancer.
Prostate. 2016 Oct 4. doi: 10.1002/pros.23258.
PubMed Text format Abstract available

IMADA K, Shiota M, Kuroiwa K, Sugimoto M, et al
FOXO3a Expression Regulated by ERK Signaling is Inversely Correlated With Y-Box Binding Protein-1 Expression in Prostate Cancer.
Prostate. 2016 Oct 4. doi: 10.1002/pros.23254.
PubMed Text format Abstract available

OTSUKI H, Kimura T, Yamaga T, Kosaka T, et al
Prostate Cancer Cells in Different Androgen Receptor Status Employ Different Leucine Transporters.
Prostate. 2016 Oct 3. doi: 10.1002/pros.23263.
PubMed Text format Abstract available

TALESA VN, Ferri I, Bellezza G, Love HD, et al
Glyoxalase 2 Is Involved in Human Prostate Cancer Progression as Part of a Mechanism Driven By PTEN/PI3K/AKT/mTOR Signaling With Involvement of PKM2 and ERalpha.
Prostate. 2016 Oct 3. doi: 10.1002/pros.23261.
PubMed Text format Abstract available

September 2016

ZUMSTEG ZS, Chen Z, Howard LE, Amling CL, et al
Number of Unfavorable Intermediate-Risk Factors Predicts Pathologic Upstaging and Prostate Cancer-Specific Mortality Following Radical Prostatectomy: Results From the SEARCH Database.
Prostate. 2016 Sep 29. doi: 10.1002/pros.23255.
PubMed Text format Abstract available

LEYH-BANNURAH SR, Gazdovich S, Budaus L, Zaffuto E, et al
Population-Based External Validation of the Updated 2012 Partin Tables in Contemporary North American Prostate Cancer Patients.
Prostate. 2016 Sep 29. doi: 10.1002/pros.23253.
PubMed Text format Abstract available

MIYAHIRA AK, Roychowdhury S, Goswami S, Ippolito JE, et al
Beyond Seed and Soil: Understanding and Targeting Metastatic Prostate Cancer; Report From the 2016 Coffey-Holden Prostate Cancer Academy Meeting.
Prostate. 2016 Sep 28. doi: 10.1002/pros.23260.
PubMed Text format Abstract available

BARRETT CS, Millena AC, Khan SA
TGF-beta Effects on Prostate Cancer Cell Migration and Invasion Require FosB.
Prostate. 2016 Sep 7. doi: 10.1002/pros.23250.
PubMed Text format Abstract available

August 2016

WULANINGSIH W, Astuti Y, Matsuguchi T, Anggrandariyanny P, et al
Circulating Prostate-Specific Antigen and Telomere Length in a Nationally Representative Sample of Men Without History of Prostate Cancer.
Prostate. 2016 Aug 27. doi: 10.1002/pros.23245.
PubMed Text format Abstract available

LEE CH, Ku JY, Ha JM, Bae SS, et al
Transcript Levels of Androgen Receptor Variant 7 and Ubiquitin-Conjugating Enzyme 2C in Hormone Sensitive Prostate Cancer and Castration-Resistant Prostate Cancer.
Prostate. 2016 Aug 22. doi: 10.1002/pros.23248.
PubMed Text format Abstract available

CHAKRAVARTHI BV, Goswami MT, Pathi SS, Dodson M, et al
Expression and Role of PAICS, a De Novo Purine Biosynthetic Gene in Prostate Cancer.
Prostate. 2016 Aug 22. doi: 10.1002/pros.23243.
PubMed Text format Abstract available

ALBRIGHT FS, Stephenson RA, Agarwal N, Cannon-Albright LA, et al
Relative Risks for Lethal Prostate Cancer Based on Complete Family History of Prostate Cancer Death.
Prostate. 2016 Aug 16. doi: 10.1002/pros.23247.
PubMed Text format Abstract available

MAUGHAN BL, Luber B, Nadal R, Antonarakis ES, et al
Comparing Sequencing of Abiraterone and Enzalutamide in Men With Metastatic Castration-Resistant Prostate Cancer: A Retrospective Study.
Prostate. 2016 Aug 16. doi: 10.1002/pros.23246.
PubMed Text format Abstract available

ASAI A, Miyata Y, Matsuo T, Shida Y, et al
Changes in Lymphangiogenesis and Vascular Endothelial Growth Factor Expression by Neo-Adjuvant Hormonal Therapy in Prostate Cancer Patients.
Prostate. 2016 Aug 16. doi: 10.1002/pros.23244.
PubMed Text format Abstract available

CASTIGLIONE F, Dell'Oglio P, Tosco L, Everaerts W, et al
Tumor Volume and Clinical Failure in High-Risk Prostate Cancer Patients Treated With Radical Prostatectomy.
Prostate. 2016 Aug 16. doi: 10.1002/pros.23242.
PubMed Text format Abstract available

FU W, Tao T, Qi M, Wang L, et al
MicroRNA-132/212 Upregulation Inhibits TGF-beta-Mediated Epithelial-Mesenchymal Transition of Prostate Cancer Cells by Targeting SOX4.
Prostate. 2016 Aug 16. doi: 10.1002/pros.23241.
PubMed Text format Abstract available

July 2016

NAKATA D, Nakayama K, Masaki T, Tanaka A, et al
Growth Inhibition by Testosterone in an Androgen Receptor Splice Variant-Driven Prostate Cancer Model.
Prostate. 2016 Jul 30. doi: 10.1002/pros.23238.
PubMed Text format Abstract available

BRUCE HM, Stricker PD, Gupta R, Savdie RR, et al
Loss of AZGP1 as a Superior Predictor of Relapse in Margin-Positive Localized Prostate Cancer.
Prostate. 2016 Jul 30. doi: 10.1002/pros.23233.
PubMed Text format Abstract available

CATHOMAS R, Crabb SJ, Mark M, Winterhalder R, et al
Orteronel Switch Maintenance Therapy in Metastatic Castration Resistant Prostate Cancer After First-Line Docetaxel: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial (SAKK 08/11).
Prostate. 2016 Jul 25. doi: 10.1002/pros.23236.
PubMed Text format Abstract available

DAI L, Li J, Xing M, Sanchez TW, et al
Using serological proteome analysis to identify serum anti-nucleophosmin 1 autoantibody as a potential biomarker in European-American and African-American patients with prostate cancer.
Prostate. 2016 Jul 15. doi: 10.1002/pros.23217.
PubMed Text format Abstract available

KOCEMBA KA, Dudzik P, Ostrowska B, Laidler P, et al
Incorrect analysis of MCAM gene promoter methylation in prostate cancer.
Prostate. 2016 Jul 15. doi: 10.1002/pros.23210.
PubMed Text format

WU JC, Wang CT, Hung HC, Wu WJ, et al
Heteronemin is a novel c-Met/STAT3 inhibitor against advanced prostate cancer cells.
Prostate. 2016 Jul 15. doi: 10.1002/pros.23230.
PubMed Text format Abstract available

WHITE-AL HABEEB NM, Garcia J, Fleshner N, Bapat B, et al
Metformin elicits antitumor effects and downregulates the histone methyltransferase multiple myeloma SET domain (MMSET) in prostate cancer cells.
Prostate. 2016 Jul 12. doi: 10.1002/pros.23235.
PubMed Text format Abstract available

MARKOWSKI MC, Frick KD, Eshleman JR, Luo J, et al
Cost-savings analysis of AR-V7 testing in patients with metastatic castration-resistant prostate cancer eligible for treatment with abiraterone or enzalutamide.
Prostate. 2016 Jul 12. doi: 10.1002/pros.23232.
PubMed Text format Abstract available

AL-BAKHEIT A, Traka M, Saha S, Mithen R, et al
Accumulation of palmitoylcarnitine and its effect on pro-inflammatory pathways and calcium influx in prostate cancer.
Prostate. 2016 Jul 12. doi: 10.1002/pros.23222.
PubMed Text format Abstract available

FARACH A, Ding Y, Lee M, Creighton C, et al
Neuronal trans-differentiation in prostate cancer cells.
Prostate. 2016 Jul 12. doi: 10.1002/pros.23221.
PubMed Text format Abstract available

GALHEIGO MR, Cruz AR, Cabral AS, Faria PR, et al
Role of the TNF-alpha receptor type 1 on prostate carcinogenesis in knockout mice.
Prostate. 2016;76:917-26.
PubMed Text format Abstract available

SARTOR O, Hoskin P, Coleman RE, Nilsson S, et al
Chemotherapy following radium-223 dichloride treatment in ALSYMPCA.
Prostate. 2016;76:905-16.
PubMed Text format Abstract available

June 2016

DOGAN A, Demirci S, Turkmen NB, Caglayan AB, et al
Schiff base-poloxamer P85 combination prevents prostate cancer progression in C57/Bl6 mice.
Prostate. 2016 Jun 24. doi: 10.1002/pros.23229.
PubMed Text format Abstract available

LIANG P, Henning SM, Schokrpur S, Wu L, et al
Effect of dietary omega-3 fatty acids on tumor-associated macrophages and prostate cancer progression.
Prostate. 2016 Jun 24. doi: 10.1002/pros.23218.
PubMed Text format Abstract available

SCHWEIZER MT, Wang H, Luber B, Nadal R, et al
Bipolar androgen therapy for men with androgen ablation naive prostate cancer: Results from the phase II BATMAN study.
Prostate. 2016 Jun 24. doi: 10.1002/pros.23209.
PubMed Text format Abstract available

CUNNINGHAM D, Parajuli KR, Zhang C, Wang G, et al
Monomethyl auristatin e phosphate inhibits human prostate cancer growth.
Prostate. 2016 Jun 21. doi: 10.1002/pros.23226.
PubMed Text format Abstract available

KULAC I, Gumuskaya B, Drake CG, Gonzalez B, et al
Peripheral zone inflammation is not strongly associated with lower urinary tract symptom incidence and progression in the placebo arm of the prostate cancer prevention trial .
Prostate. 2016 Jun 21. doi: 10.1002/pros.23224.
PubMed Text format Abstract available

XIE W, Drouin S, Nakabayashi M, Pomerantz M, et al
A genetic variation of SOD2 does not determine duration of response to androgen deprivation therapy for prostate cancer.
Prostate. 2016 Jun 21. doi: 10.1002/pros.23220.
PubMed Text format Abstract available

CHENG HH, Klemfuss N, Montgomery B, Higano CS, et al
A pilot study of clinical targeted next generation sequencing for prostate cancer: Consequences for treatment and genetic counseling.
Prostate. 2016 Jun 21. doi: 10.1002/pros.23219.
PubMed Text format Abstract available

JUNGHANS RP, Ma Q, Rathore R, Gomes EM, et al
Phase I trial of anti-PSMA designer CAR-T cells in prostate cancer: Possible role for interacting interleukin 2-T cell pharmacodynamics as a determinant of clinical response.
Prostate. 2016 Jun 21. doi: 10.1002/pros.23214.
PubMed Text format Abstract available

MURPHY C, True L, Vakar-Lopez F, Xia J, et al
A novel system for estimating residual disease and pathologic response to neoadjuvant treatment of prostate cancer.
Prostate. 2016 Jun 8. doi: 10.1002/pros.23215.
PubMed Text format Abstract available

XIAO L, Lanz RB, Frolov A, Castro PD, et al
The germ cell gene TDRD1 as an ERG target gene and a novel prostate cancer biomarker.
Prostate. 2016 Jun 8. doi: 10.1002/pros.23213.
PubMed Text format Abstract available

SHAHABI A, Lewinger JP, Ren J, April C, et al
Novel gene expression signature predictive of clinical recurrence after radical prostatectomy in early stage prostate cancer patients.
Prostate. 2016 Jun 8. doi: 10.1002/pros.23211.
PubMed Text format Abstract available

MIYAHIRA AK, Simons JW, Soule HR
The 22nd annual prostate cancer foundation scientific retreat report.
Prostate. 2016 Jun 8. doi: 10.1002/pros.23193.
PubMed Text format Abstract available

SAETER T, Vlatkovic L, Waaler G, Servoll E, et al
Combining lymphovascular invasion with reactive stromal grade predicts prostate cancer mortality.
Prostate. 2016 Jun 8. doi: 10.1002/pros.23192.
PubMed Text format Abstract available

SHOURIDEH M, DePriest A, Mohler JL, Wilson EM, et al
Characterization of fibroblast-free CWR-R1ca castration-recurrent prostate cancer cell line.
Prostate. 2016 Jun 8. doi: 10.1002/pros.23190.
PubMed Text format Abstract available

ANTWI SO, Steck SE, Su LJ, Hebert JR, et al
Carotenoid intake and adipose tissue carotenoid levels in relation to prostate cancer aggressiveness among African-American and European-American men in the North Carolina-Louisiana prostate cancer project (PCaP).
Prostate. 2016 Jun 8. doi: 10.1002/pros.23189.
PubMed Text format Abstract available

GERRIN SJ, Sowalsky AG, Balk SP, Ye H, et al
Mutation profiling indicates high grade prostatic intraepithelial neoplasia as distant precursors of adjacent invasive prostatic adenocarcinoma.
Prostate. 2016 Jun 8. doi: 10.1002/pros.23212.
PubMed Text format Abstract available

UDAGER AM, DeMarzo AM, Shi Y, Hicks JL, et al
Concurrent nuclear ERG and MYC protein overexpression defines a subset of locally advanced prostate cancer: Potential opportunities for synergistic targeted therapeutics.
Prostate. 2016;76:845-53.
PubMed Text format Abstract available

PAN X, Zhang X, Gong J, Tan J, et al
The expression profile and prognostic value of SPINK1 in initially diagnosed bone metastatic prostate cancer.
Prostate. 2016;76:823-33.
PubMed Text format Abstract available

MCILWAIN DW, Zoetemelk M, Myers JD, Edwards MT, et al
Coordinated induction of cell survival signaling in the inflamed microenvironment of the prostate.
Prostate. 2016;76:722-34.
PubMed Text format Abstract available

HENNING JD, Bunker CH, Patrick AL, Jenkins FJ, et al
Human herpesvirus 8 establishes a latent infection in prostates of Tobago men resulting in increased macrophage infiltration.
Prostate. 2016;76:735-43.
PubMed Text format Abstract available

AKINBOYE ES, Brennen WN, Rosen DM, Bakare O, et al
Iterative design of emetine-based prodrug targeting fibroblast activation protein (FAP) and dipeptidyl peptidase IV DPPIV using a tandem enzymatic activation strategy.
Prostate. 2016;76:703-14.
PubMed Text format Abstract available

May 2016

ELLIS L, Ku S, Li Q, Azabdaftari G, et al
Generation of a C57BL/6 MYC-driven mouse model and cell line of prostate cancer.
Prostate. 2016 May 26. doi: 10.1002/pros.23206.
PubMed Text format Abstract available

GLEICHER S, Kauffman EC, Kotula L, Bratslavsky G, et al
Implications of high rates of metastatic prostate cancer in BRCA2 mutation carriers.
Prostate. 2016 May 26. doi: 10.1002/pros.23204.
PubMed Text format Abstract available

KRYVENKO ON, Epstein JI
Re: Clinical significance of prospectively assigned gleason tertiary pattern 4 in contemporary Gleason score 3 + 3 = 6 prostate cancer.
Prostate. 2016 May 26. doi: 10.1002/pros.23199.
PubMed Text format

CUI T, Hester AG, Seeds MC, Rahbar E, et al
Impact of genetic and epigenetic variations within the FADS cluster on the composition and metabolism of polyunsaturated fatty acids in prostate cancer.
Prostate. 2016 May 16. doi: 10.1002/pros.23205.
PubMed Text format Abstract available

MUTHUSWAMY R, Corman JM, Dahl K, Chatta GS, et al
Functional reprogramming of human prostate cancer to promote local attraction of effector CD8 T cells.
Prostate. 2016 May 16. doi: 10.1002/pros.23194.
PubMed Text format Abstract available

HECK MM, Thalgott M, Schmid SC, Oh WK, et al
A 2-gene panel derived from prostate cancer-enhanced transcripts in whole blood is prognostic for survival and predicts treatment benefit in metastatic castration-resistant prostate cancer.
Prostate. 2016 May 16. doi: 10.1002/pros.23202.
PubMed Text format Abstract available

LYNCH SM, O'Neill KM, McKenna MM, Walsh CP, et al
Regulation of miR-200c and miR-141 by methylation in prostate cancer.
Prostate. 2016 May 16. doi: 10.1002/pros.23201.
PubMed Text format Abstract available

CHEN H, Liu X, Brendler CB, Ankerst DP, et al
Adding genetic risk score to family history identifies twice as many high-risk men for prostate cancer: Results from the prostate cancer prevention trial.
Prostate. 2016 May 16. doi: 10.1002/pros.23200.
PubMed Text format Abstract available

KUMAR D, Gupta A, Mandhani A, Sankhwar SN, et al
NMR spectroscopy of filtered serum of prostate cancer: A new frontier in metabolomics.
Prostate. 2016 May 16. doi: 10.1002/pros.23198.
PubMed Text format Abstract available

GREENE DJ, Elshafei A, Nyame YA, Kara O, et al
External validation of a PCA-3-based nomogram for predicting prostate cancer and high-grade cancer on initial prostate biopsy.
Prostate. 2016 May 16. doi: 10.1002/pros.23197.
PubMed Text format Abstract available

LARBI A, Dallaudiere B, Pasoglou V, Padhani A, et al
Whole body MRI (WB-MRI) assessment of metastatic spread in prostate cancer: Therapeutic perspectives on targeted management of oligometastatic disease.
Prostate. 2016 May 16. doi: 10.1002/pros.23196.
PubMed Text format Abstract available

SAKAI M, Martinez-Arguelles DB, Aprikian AG, Magliocco AM, et al
De novo steroid biosynthesis in human prostate cell lines and biopsies.
Prostate. 2016;76:575-87.
PubMed Text format Abstract available

PADMANABHAN A, Rao V, De Marzo AM, Bieberich CJ, et al
Regulating NKX3.1 stability and function: Post-translational modifications and structural determinants.
Prostate. 2016;76:523-33.
PubMed Text format Abstract available

BRENNEN WN, Kisteman LN, Isaacs JT
Rapid selection of mesenchymal stem and progenitor cells in primary prostate stromal cultures.
Prostate. 2016;76:552-64.
PubMed Text format Abstract available

HEGER Z, Gumulec J, Cernei N, Polanska H, et al
Relation of exposure to amino acids involved in sarcosine metabolic pathway on behavior of non-tumor and malignant prostatic cell lines.
Prostate. 2016;76:679-90.
PubMed Text format Abstract available

April 2016

VAN NESTE L, Partin AW, Stewart GD, Epstein JI, et al
Risk score predicts high-grade prostate cancer in DNA-methylation positive, histopathologically negative biopsies.
Prostate. 2016 Apr 28. doi: 10.1002/pros.23191.
PubMed Text format Abstract available

YOSHIKAWA T, Kobori G, Goto T, Akamatsu S, et al
An original patient-derived xenograft of prostate cancer with cyst formation.
Prostate. 2016 Apr 21. doi: 10.1002/pros.23188.
PubMed Text format Abstract available

SZARVAS T, Reis H, Vom Dorp F, Tschirdewahn S, et al
Soluble syndecan-1 (SDC1) serum level as an independent pre-operative predictor of cancer-specific survival in prostate cancer.
Prostate. 2016 Apr 7. doi: 10.1002/pros.23186.
PubMed Text format Abstract available

GUAN Y, Wu Y, Liu Y, Ni J, et al
Association of microRNA-21 expression with clinicopathological characteristics and the risk of progression in advanced prostate cancer patients receiving androgen deprivation therapy.
Prostate. 2016 Apr 4. doi: 10.1002/pros.23187.
PubMed Text format Abstract available

TUMMALA R, Nadiminty N, Lou W, Evans CP, et al
Lin28 induces resistance to anti-androgens via promotion of AR splice variant generation.
Prostate. 2016;76:445-55.
PubMed Text format Abstract available

KESKIVALI T, Kujala P, Visakorpi T, Tammela TL, et al
Statin use and risk of disease recurrence and death after radical prostatectomy.
Prostate. 2016;76:469-78.
PubMed Text format Abstract available

March 2016

CHA YJ, Lee JH, Han HH, Kim BG, et al
MicroRNA alteration and putative target genes in high-grade prostatic intraepithelial neoplasia and prostate cancer: STAT3 and ZEB1 are upregulated during prostate carcinogenesis.
Prostate. 2016 Mar 28. doi: 10.1002/pros.23183.
PubMed Text format Abstract available

DE MORREE E, van Soest R, Aghai A, de Ridder C, et al
Understanding taxanes in prostate cancer; importance of intratumoral drug accumulation.
Prostate. 2016 Mar 21. doi: 10.1002/pros.23182.
PubMed Text format Abstract available

ROUDIER MP, Winters BR, Coleman I, Lam HM, et al
Characterizing the molecular features of ERG-positive tumors in primary and castration resistant prostate cancer.
Prostate. 2016 Mar 16. doi: 10.1002/pros.23171.
PubMed Text format Abstract available

NAM RK, Benatar T, Wallis CJ, Amemiya Y, et al
MiR-301a regulates E-cadherin expression and is predictive of prostate cancer recurrence.
Prostate. 2016 Mar 15. doi: 10.1002/pros.23177.
PubMed Text format Abstract available

CREMERS RG, Aben KK, van Oort IM, Sedelaar JP, et al
The clinical phenotype of hereditary versus sporadic prostate cancer: HPC definition revisited.
Prostate. 2016 Mar 14. doi: 10.1002/pros.23179.
PubMed Text format Abstract available

HERNANDEZ S, Font-Tello A, Juanpere N, de Muga S, et al
Concurrent TMPRSS2-ERG and SLC45A3-ERG rearrangements plus PTEN loss are not found in low grade prostate cancer and define an aggressive tumor subset.
Prostate. 2016 Mar 9. doi: 10.1002/pros.23176.
PubMed Text format Abstract available

DING H, Kothandaraman S, Gong L, Williams MM, et al
A human GRPr-transfected Ace-1 canine prostate cancer model in mice.
Prostate. 2016 Mar 4. doi: 10.1002/pros.23172.
PubMed Text format Abstract available

ELSHAFAE SM, Hassan BB, Supsavhad W, Dirksen WP, et al
Gastrin-releasing peptide receptor (GRPr) promotes EMT, growth, and invasion in canine prostate cancer.
Prostate. 2016 Mar 4. doi: 10.1002/pros.23154.
PubMed Text format Abstract available

TORABI-NEZHAD S, Malekmakan L, Mashayekhi M, Daneshian A, et al
Histopathological features of intra-ductal carcinoma of prostatic and high grade prostatic intraepithelialneoplasia and correlation with PTEN and P63.
Prostate. 2016;76:394-401.
PubMed Text format Abstract available

February 2016

HIJAZI S, Meller B, Leitsmann C, Strauss A, et al
See the unseen: Mesorectal lymph node metastases in prostate cancer.
Prostate. 2016 Feb 16. doi: 10.1002/pros.23168.
PubMed Text format Abstract available

FORBES A, Anoopkumar-Dukie S, Chess-Williams R, McDermott C, et al
Relative cytotoxic potencies and cell death mechanisms of alpha -adrenoceptor antagonists in prostate cancer cell lines.
Prostate. 2016 Feb 16. doi: 10.1002/pros.23167.
PubMed Text format Abstract available

DOSHI C, Vacchio M, Attwood K, Murekeyisoni C, et al
Clinical significance of prospectively assigned Gleason tertiary pattern 4 in contemporary Gleason score 3+3=6 prostate cancer.
Prostate. 2016 Feb 16. doi: 10.1002/pros.23166.
PubMed Text format Abstract available

HORIGUCHI A, Tsujita K, Irisawa K, Kasamatsu T, et al
A pilot study of photoacoustic imaging system for improved real-time visualization of neurovascular bundle during radical prostatectomy.
Prostate. 2016;76:307-15.
PubMed Text format Abstract available

NOSOV A, Reva S, Petrov S, Mamijev E, et al
Neoadjuvant chemotherapy using reduced-dose docetaxel followed by radical prostatectomy for patients with intermediate and high-risk prostate cancer: a single-center study.
Prostate. 2016 Feb 11. doi: 10.1002/pros.23165.
PubMed Text format Abstract available

KAWAHARA T, Aljarah AK, Shareef HK, Inoue S, et al
Silodosin inhibits prostate cancer cell growth via ELK1 inactivation and enhances the cytotoxic activity of gemcitabine.
Prostate. 2016 Feb 11. doi: 10.1002/pros.23164.
PubMed Text format Abstract available

CHA HR, Lee JH, Hensel JA, Sawant AB, et al
Prostate cancer-derived cathelicidin-related antimicrobial peptide facilitates macrophage differentiation and polarization of immature myeloid progenitors to protumorigenic macrophages.
Prostate. 2016 Feb 9. doi: 10.1002/pros.23155.
PubMed Text format Abstract available

XIE W, Yang M, Chan J, Sun T, et al
Association of genetic variations of selenoprotein genes, plasma selenium levels, and prostate cancer aggressiveness at diagnosis.
Prostate. 2016 Feb 5. doi: 10.1002/pros.23160.
PubMed Text format Abstract available

LIU X, Han W, Gulla S, Simon NI, et al
Androgen ablation elicits PP1-dependence for AR stabilization and transactivation in prostate cancer.
Prostate. 2016 Feb 5. doi: 10.1002/pros.23157.
PubMed Text format Abstract available

LYNCH SM, McKenna MM, Walsh CP, McKenna DJ, et al
miR-24 regulates CDKN1B/p27 expression in prostate cancer.
Prostate. 2016 Feb 5. doi: 10.1002/pros.23156.
PubMed Text format Abstract available

MELLING N, Taskin B, Hube-Magg C, Kluth M, et al
Cytoplasmic accumulation of ELAVL1 is an independent predictor of biochemical recurrence associated with genomic instability in prostate cancer.
Prostate. 2016;76:259-72.
PubMed Text format Abstract available

NICKKHOLGH B, Fang X, Winters SM, Raina A, et al
Cell line modeling to study biomarker panel in prostate cancer.
Prostate. 2016;76:245-58.
PubMed Text format Abstract available

NIRAULA S, Templeton AJ, Vera-Badillo FE, Joshua AM, et al
Study of testosterone-guided androgen deprivation therapy in management of prostate cancer.
Prostate. 2016;76:235-42.
PubMed Text format Abstract available

ARAUJO CL, Quintero IB, Ovaska K, Herrala AM, et al
Transmembrane prostatic acid phosphatase (TMPAP) delays cells in G1 phase of the cell cycle.
Prostate. 2016;76:151-62.
PubMed Text format Abstract available

January 2016

SHUI IM, Kolb S, Hanson C, Sutcliffe S, et al
Trichomonas vaginalis infection and risk of advanced prostate cancer.
Prostate. 2016 Jan 28. doi: 10.1002/pros.23153.
PubMed Text format Abstract available

NAKKEN HL, Lephart ED, Hopkins TJ, Shaw B, et al
Prenatal exposure to soy and selenium reduces prostate cancer risk factors in TRAMP mice more than exposure beginning at six weeks.
Prostate. 2016 Jan 28. doi: 10.1002/pros.23150.
PubMed Text format Abstract available

VON HARDENBERG J, Schwartz M, Werner T, Fuxius S, et al
Influence of abiraterone acetate on circulating neuromediators in chemotherapy-naive castration-resistant prostate cancer.
Prostate. 2016 Jan 15. doi: 10.1002/pros.23152.
PubMed Text format Abstract available

HU BR, Fairey AS, Madhav A, Yang D, et al
AXIN2 expression predicts prostate cancer recurrence and regulates invasion and tumor growth.
Prostate. 2016 Jan 15. doi: 10.1002/pros.23151.
PubMed Text format Abstract available

WINCHESTER DA, Gurel B, Till C, Goodman PJ, et al
Key genes involved in the immune response are generally not associated with intraprostatic inflammation in men without a prostate cancer diagnosis: Results from the prostate cancer prevention trial.
Prostate. 2016 Jan 15. doi: 10.1002/pros.23147.
PubMed Text format Abstract available

FU X, Zhang W, Su Y, Lu L, et al
MicroRNA-103 suppresses tumor cell proliferation by targeting PDCD10 in prostate cancer.
Prostate. 2016 Jan 15. doi: 10.1002/pros.23143.
PubMed Text format Abstract available

PAXIMADIS P, Najy AJ, Snyder M, Kim HC, et al
The interaction between androgen receptor and PDGF-D in the radiation response of prostate carcinoma.
Prostate. 2016 Jan 6. doi: 10.1002/pros.23135.
PubMed Text format Abstract available

HOFNER T, Klein C, Eisen C, Rigo-Watermeier T, et al
The influence of prostatic anatomy and neurotrophins on basal prostate epithelial progenitor cells.
Prostate. 2016;76:114-21.
PubMed Text format Abstract available

PEDROSA AR, Graca JL, Carvalho S, Peleteiro MC, et al
Notch signaling dynamics in the adult healthy prostate and in prostatic tumor development.
Prostate. 2016;76:80-96.
PubMed Text format Abstract available

CORBIN JM, Overcash RF, Wren JD, Coburn A, et al
Analysis of TMEFF2 allografts and transgenic mouse models reveals roles in prostate regeneration and cancer.
Prostate. 2016;76:97-113.
PubMed Text format Abstract available

December 2015

HERRMANN VL, Wieland DE, Legler DF, Wittmann V, et al
The STEAP1 peptide encapsulated into PLGA microspheres elicits strong cytotoxic T cell immunity in HLA-A*0201 transgenic mice-a new approach to immunotherapy against prostate carcinoma.
Prostate. 2015 Dec 30. doi: 10.1002/pros.23136.
PubMed Text format Abstract available

KRYVENKO ON, Epstein JI
Changes in prostate cancer grading: Including a new patient-centric grading system.
Prostate. 2015 Dec 28. doi: 10.1002/pros.23142.
PubMed Text format Abstract available

KIBEL AS, Ahn J, Isikbay M, Klim A, et al
Genetic variants in cell cycle control pathway confer susceptibility to aggressive prostate carcinoma.
Prostate. 2015 Dec 28. doi: 10.1002/pros.23139.
PubMed Text format Abstract available

KARATAS OF, Guzel E, Duz MB, Ittmann M, et al
The role of ATP-binding cassette transporter genes in the progression of prostate cancer.
Prostate. 2015 Dec 28. doi: 10.1002/pros.23137.
PubMed Text format Abstract available

NADAL R, Tsai HL, Sinibaldi VJ, Paller CJ, et al
Prognostic factors for clinical outcomes in patients with metastatic castration resistant prostate cancer treated with sequential novel androgen receptor-directed therapies.
Prostate. 2015 Dec 22. doi: 10.1002/pros.23141.
PubMed Text format Abstract available

MAGNUSSON LU, Hagberg MT, Plas P, Olsson A, et al
Tasquinimod inhibits prostate cancer growth in bone through alterations in the bone microenvironment.
Prostate. 2015 Dec 10. doi: 10.1002/pros.23133.
PubMed Text format Abstract available

MCCROW JP, Petersen DC, Louw M, Chan EK, et al
Spectrum of mitochondrial genomic variation and associated clinical presentation of prostate cancer in South African men.
Prostate. 2015 Dec 10. doi: 10.1002/pros.23126.
PubMed Text format Abstract available

RAUSCHENBERGER L, Staar D, Thom K, Scharf C, et al
Exosomal particles secreted by prostate cancer cells are potent mRNA and protein vehicles for the interference of tumor and tumor environment.
Prostate. 2015 Dec 8. doi: 10.1002/pros.23132.
PubMed Text format Abstract available

SEEDHOUSE SJ, Affronti HC, Karasik E, Gillard BM, et al
Metastatic phenotype in CWR22 prostate cancer xenograft following castration.
Prostate. 2015 Dec 8. doi: 10.1002/pros.23127.
PubMed Text format Abstract available

PAYNE ONDRACEK R, Cheng J, Gangavarapu KJ, Azabdaftari G, et al
Impact of devascularization and tissue procurement on cell number and RNA integrity in prostatectomy tissue.
Prostate. 2015;75:1910-5.
PubMed Text format Abstract available

ZAPATA D, Howard LE, Allott EH, Hamilton RJ, et al
Is PSA related to serum cholesterol and does the relationship differ between black and white men?
Prostate. 2015;75:1877-85.
PubMed Text format Abstract available

November 2015

MIYOSHI Y, Uemura H, Umemoto S, Sakamaki K, et al
Low serum dehydroepiandrosterone examined by liquid chromatography-tandem mass spectrometry correlates with poor prognosis in hormone-naive prostate cancer.
Prostate. 2015 Nov 30. doi: 10.1002/pros.23129.
PubMed Text format Abstract available

BONKHOFF H
Significance of prostate cancer missed on needle biopsy tools for retrieving missed cancer.
Prostate. 2015 Nov 30. doi: 10.1002/pros.23128.
PubMed Text format Abstract available

NORDSTROM T, Van Blarigan EL, Ngo V, Roy R, et al
Associations between circulating carotenoids, genomic instability and the risk of high-grade prostate cancer.
Prostate. 2015 Nov 20. doi: 10.1002/pros.23125.
PubMed Text format Abstract available

DIPIPPO VA, Nguyen HM, Brown LG, Olson WC, et al
Addition of PSMA ADC to enzalutamide therapy significantly improves survival in in vivo model of castration resistant prostate cancer.
Prostate. 2015 Nov 20. doi: 10.1002/pros.23124.
PubMed Text format Abstract available

HORNING AM, Awe JA, Wang CM, Liu J, et al
DNA methylation screening of primary prostate tumors identifies SRD5A2 and CYP11A1 as candidate markers for assessing risk of biochemical recurrence.
Prostate. 2015;75:1790-801.
PubMed Text format Abstract available

NORDBY Y, Andersen S, Richardsen E, Ness N, et al
Stromal expression of VEGF-A and VEGFR-2 in prostate tissue is associated with biochemical and clinical recurrence after radical prostatectomy.
Prostate. 2015;75:1682-93.
PubMed Text format Abstract available

WINTERS B, Plymate S, Zeliadt SB, Holt S, et al
Metformin effects on biochemical recurrence and metabolic signaling in the prostate.
Prostate. 2015;75:1694-703.
PubMed Text format Abstract available

September 2015

LIU Y, Zhao X, Sun X, Li Y, et al
Expression of IL-17A, E, and F and their receptors in human prostatic cancer: Comparison with benign prostatic hyperplasia.
Prostate. 2015 Sep 10. doi: 10.1002/pros.23058.
PubMed Text format Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: